Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UTAA 06 gamma delta Tcell therapy

Next Previous
Drug Profile

UTAA 06 gamma delta Tcell therapy

Alternative Names: CAR gene modified gamma delta T cell injection - PersonGen BioTherapeutics; CAR gene modified gdT cell injection; CAR gene modified gdT cell injection - PersonGen BioTherapeutics; UTAA-06; UTAA06 injection; UTAA06-γδT

Latest Information Update: 23 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PersonGen Biotherapeutics
  • Developer Peking University; PersonGen Biotherapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Solid tumours

Most Recent Events

  • 01 Dec 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (Parenteral) (NCT06372236)
  • 19 Feb 2023 Clinical trials in Solid tumours in China (Parenteral) (Biotherapeutics pipeline; February 2023)
  • 19 Feb 2023 Preclinical trials in Solid tumours in China (Parenteral) (Biotherapeutics pipeline; February 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top